title: Bioabsorbable polyphosphazene matrices as systems for calcitonin controlled release.
abstract: To provide a suitable delivery system for the calcitonin controlled release 80 mg bioabsorbable polyphosphazene matrices were obtained with entrapped 50 or 250 micrograms calcitonin. The in vitro behaviour demonstrated a release burst for about 24 hours, followed by a period of slow release of the peptide lasting for weeks. Matrices containing 250 micrograms calcitonin were implanted under general anaesthesia in osteoporotic female rats, while a group of animals (control group) received unloaded matrices. After thirty days a second batch of matrices was implanted in both groups to prolong the period of treatment until two months. The explanted matrices were histologically evaluated together with the surrounding tissues, and the dosage of the residual calcitonin was also performed. Results demonstrated the good biocompatibility of the system and the complete release of the calcitonin from the matrices 30 days after implantation. The therapeutic effect, after sixty days of treatment was confirmed by the better densitometric values observed in the femoral bone of treated animals than in controls.
authors.affiliation: Department of Pharmaceutical Sciences, University of Padova, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Caliceti
authors.forename: N
authors.initials: N
authors.lastname: Nicoli Aldini
authors.forename: M
authors.initials: M
authors.lastname: Fini
authors.forename: M
authors.initials: M
authors.lastname: Rocca
authors.forename: S
authors.initials: S
authors.lastname: Gnudi
authors.forename: S
authors.initials: S
authors.lastname: Lora
authors.forename: G
authors.initials: G
authors.lastname: Giavaresi
authors.forename: C
authors.initials: C
authors.lastname: Monfardini
authors.forename: R
authors.initials: R
authors.lastname: Giardino
authors.forename: F M
authors.initials: FM
authors.lastname: Veronese
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000378:metabolism*; D002116:Calcitonin / Q000008:administration & dosage* / Q000032:analysis / Q000627:therapeutic use; D004343:Drug Implants; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009943:Organophosphorus Compounds / Q000378:metabolism*; D010024:Osteoporosis / Q000188:drug therapy; D011108:Polymers / Q000378:metabolism*; D051381:Rats
chemical_list: D001672:Biocompatible Materials; D004343:Drug Implants; D009943:Organophosphorus Compounds; D011108:Polymers; C108974:poly(phosphazene); D002116:Calcitonin